PB 58 of 2012
National Health (Weighted average disclosed price – interim supplementary disclosure cycle) Determination 2012
as amended
made under subsection 99ADB(4) and paragraph 99ADH(1)(aa) of the
National Health Act 1953
This compilation was prepared on 5 November 2012
taking into account amendments up to PB 98 of 2012
Prepared by the Office of Parliamentary Counsel, Canberra
Contents
1 Name of Determination [see Note 1]
2 Commencement [see Note 1]
3 Definitions
4 Weighted average disclosed price for brands of pharmaceutical items – unadjusted price reduction is at least 10%
5 Weighted average disclosed price for brands of pharmaceutical items – unadjusted price reduction is less than 10%
6 Adjusted approved ex‑manufacturer price for brands of pharmaceutical items – unadjusted price reduction is at least 10%
7 Adjusted approved price to pharmacists for brands of pharmaceutical items – unadjusted price reduction is at least 10%
8 Reduction Day
Schedule 1 Brands of pharmaceutical items – unadjusted price reduction is at least 10%
Schedule 2 Brands of pharmaceutical items – unadjusted price reduction is less than 10%
Notes
1 Name of Determination [see Note 1]
(1) This Determination is the National Health (Weighted average disclosed price – interim supplementary disclosure cycle) Determination 2012.
(2) This Determination may also be cited as PB 58 of 2012.
2 Commencement [see Note 1]
This Determination commences on the day after it is registered.
3 Definitions
In this Determination:
Act means the National Health Act 1953.
adjusted approved ex‑manufacturer price has the same meaning as in subsection 99ADB(1) of the Act.
adjusted approved price to pharmacists has the same meaning as in subsection 99ADB(1) of the Act.
interim supplementary disclosure cycle has the same meaning as paragraph 37EB (2) (b), of the National Health (Pharmaceutical Benefits) Regulations 1960.
unadjusted price reduction has the same meaning as in subsection 99ADB(1) of the Act.
weighted average disclosed price has the same meaning as in subsection 99ADB(1) of the Act.
4 Weighted average disclosed price for brands of pharmaceutical items – unadjusted price reduction is at least 10%
For subsection 99ADB(4) of the Act, the weighted average disclosed price specified in column 3 of an item in Schedule 1 is the weighted average disclosed price for the brand of pharmaceutical item specified in column 2 of the same item in Schedule 1.
5 Weighted average disclosed price for brands of pharmaceutical items – unadjusted price reduction is less than 10%
For subsection 99ADB(4) of the Act, the weighted average disclosed price specified in column 3 of an item in Schedule 2 is the weighted average disclosed price for the brand of pharmaceutical item specified in column 2 of the same item in Schedule 2.
6 Adjusted approved ex‑manufacturer price for brands of pharmaceutical items – unadjusted price reduction is at least 10%
For paragraph 99ADB(4) of the Act, the adjusted approved ex‑manufacturer price for a brand of pharmaceutical item specified in column 2 of Schedule 1 is an amount equal to the amount of the weighted average disclosed price of that brand of pharmaceutical item determined under section 4 of this instrument.
7 Adjusted approved price to pharmacists for brands of pharmaceutical items – unadjusted price reduction is at least 10%
For paragraph 99ADB(4) of the Act, the adjusted approved price to pharmacists specified in column 4 of an item in Schedule 1 is the adjusted approved price to pharmacists for the brand of pharmaceutical item specified in column 2 of the same item in Schedule 1.
8 Reduction Day
For paragraph 99ADH(1)(aa) of the Act, a brand of pharmaceutical item in the interim supplementary disclosure cycle with a data collection period ending at the end of 31 May 2012 has a reduction day of 1 December 2012.
Schedule 1 Brands of pharmaceutical items – unadjusted price reduction is at least 10%
Column 1 | Column 2 | Column 3 | Column 4 | |||
Item | Brand of Pharmaceutical Item | Weighted average disclosed price | Adjusted approved price to pharmacists | |||
| Listed Drug | Form | Manner of administration | Brand |
|
|
2 | Docetaxel | Injection set containing 1 single use vial concentrate for I.V. infusion 80 mg (anhydrous) in 2 mL with solvent | Injection | Taxotere | 267.72 |
|
3 | Docetaxel | Powder for I.V. infusion 20 mg with solvent | Injection | Docetaxel SUN | 66.80 |
|
4 | Docetaxel | Powder for I.V. infusion 80 mg with solvent | Injection | Docetaxel SUN | 267.72 |
|
5 | Docetaxel | Solution concentrate for I.V. infusion 140 mg in 7 mL | Injection | Oncotaxel 140 | 466.48 |
|
6 | Docetaxel | Solution concentrate for I.V. infusion 160 mg in 16 mL | Injection | DBL Docetaxel Concentrated Injection | 535.44 |
|
7 | Docetaxel | Solution concentrate for I.V. infusion 20 mg in 1 mL | Injection | Oncotaxel 20 | 66.80 |
|
8 | Docetaxel | Solution concentrate for I.V. infusion 20 mg in 1 mL | Injection | Taxotere | 66.80 |
|
9 | Docetaxel | Solution concentrate for I.V. infusion 20 mg in 2 mL | Injection | DBL Docetaxel Concentrated Injection | 66.80 |
|
10 | Docetaxel | Solution concentrate for I.V. infusion 20 mg in 2 mL | Injection | Docetaxel Ebewe | 66.80 |
|
11 | Docetaxel | Solution concentrate for I.V. infusion 20 mg in 2 mL | Injection | Docetaxel Sandoz | 66.80 |
|
12 | Docetaxel | Solution concentrate for I.V. infusion 80 mg in 4 mL | Injection | Oncotaxel 80 | 267.72 |
|
13 | Docetaxel | Solution concentrate for I.V. infusion 80 mg in 4 mL | Injection | Taxotere | 267.72 |
|
14 | Docetaxel | Solution concentrate for I.V. infusion 80 mg in 8 mL | Injection | DBL Docetaxel Concentrated Injection | 267.72 |
|
15 | Docetaxel | Solution concentrate for I.V. infusion 80 mg in 8 mL | Injection | Docetaxel Ebewe | 267.72 |
|
16 | Docetaxel | Solution concentrate for I.V. infusion 80 mg in 8 mL | Injection | Docetaxel Sandoz | 267.72 |
|
17 | Pioglitazone | Tablet 15 mg (as hydrochloride) | Oral | Acpio 15 | 27.74 | 29.83 |
18 | Pioglitazone | Tablet 15 mg (as hydrochloride) | Oral | Actos | 27.74 | 29.83 |
19 | Pioglitazone | Tablet 15 mg (as hydrochloride) | Oral | APOTEX‑Pioglitazone | 27.74 | 29.83 |
20 | Pioglitazone | Tablet 15 mg (as hydrochloride) | Oral | Chem mart Pioglitazone | 27.74 | 29.83 |
21 | Pioglitazone | Tablet 15 mg (as hydrochloride) | Oral | Pharmacor Pioglitazone 15 | 27.74 | 29.83 |
22 | Pioglitazone | Tablet 15 mg (as hydrochloride) | Oral | Pioglitazone generichealth 15 | 27.74 | 29.83 |
23 | Pioglitazone | Tablet 15 mg (as hydrochloride) | Oral | Pioglitazone Sandoz | 27.74 | 29.83 |
24 | Pioglitazone | Tablet 15 mg (as hydrochloride) | Oral | Pioglitazone‑GA | 27.74 | 29.83 |
25 | Pioglitazone | Tablet 15 mg (as hydrochloride) | Oral | Pizaccord | 27.74 | 29.83 |
25A | Pioglitazone | Tablet 15 mg (as hydrochloride) | Oral | Prioten 15 | 27.74 | 29.83 |
26 | Pioglitazone | Tablet 15 mg (as hydrochloride) | Oral | Terry White Chemists Pioglitazone | 27.74 | 29.83 |
27 | Pioglitazone | Tablet 15 mg (as hydrochloride) | Oral | Vexazone | 27.74 | 29.83 |
28 | Pioglitazone | Tablet 30 mg (as hydrochloride) | Oral | Acpio 30 | 42.67 | 45.88 |
29 | Pioglitazone | Tablet 30 mg (as hydrochloride) | Oral | Actos | 42.67 | 45.88 |
30 | Pioglitazone | Tablet 30 mg (as hydrochloride) | Oral | APOTEX‑Pioglitazone | 42.67 | 45.88 |
31 | Pioglitazone | Tablet 30 mg (as hydrochloride) | Oral | Chem mart Pioglitazone | 42.67 | 45.88 |
32 | Pioglitazone | Tablet 30 mg (as hydrochloride) | Oral | Pharmacor Pioglitazone 30 | 42.67 | 45.88 |
33 | Pioglitazone | Tablet 30 mg (as hydrochloride) | Oral | Pioglitazone generichealth 30 | 42.67 | 45.88 |
34 | Pioglitazone | Tablet 30 mg (as hydrochloride) | Oral | Pioglitazone Sandoz | 42.67 | 45.88 |
35 | Pioglitazone | Tablet 30 mg (as hydrochloride) | Oral | Pioglitazone‑GA | 42.67 | 45.88 |
36 | Pioglitazone | Tablet 30 mg (as hydrochloride) | Oral | Pizaccord | 42.67 | 45.88 |
36A | Pioglitazone | Tablet 30 mg (as hydrochloride) | Oral | Prioten 30 | 42.67 | 45.88 |
37 | Pioglitazone | Tablet 30 mg (as hydrochloride) | Oral | Terry White Chemists Pioglitazone | 42.67 | 45.88 |
38 | Pioglitazone | Tablet 30 mg (as hydrochloride) | Oral | Vexazone | 42.67 | 45.88 |
39 | Pioglitazone | Tablet 45 mg (as hydrochloride) | Oral | Acpio 45 | 55.48 | 59.65 |
40 | Pioglitazone | Tablet 45 mg (as hydrochloride) | Oral | Actos | 55.48 | 59.65 |
41 | Pioglitazone | Tablet 45 mg (as hydrochloride) | Oral | APOTEX‑Pioglitazone | 55.48 | 59.65 |
42 | Pioglitazone | Tablet 45 mg (as hydrochloride) | Oral | Chem mart Pioglitazone | 55.48 | 59.65 |
43 | Pioglitazone | Tablet 45 mg (as hydrochloride) | Oral | Pharmacor Pioglitazone 45 | 55.48 | 59.65 |
44 | Pioglitazone | Tablet 45 mg (as hydrochloride) | Oral | Pioglitazone generichealth 45 | 55.48 | 59.65 |
45 | Pioglitazone | Tablet 45 mg (as hydrochloride) | Oral | Pioglitazone Sandoz | 55.48 | 59.65 |
46 | Pioglitazone | Tablet 45 mg (as hydrochloride) | Oral | Pioglitazone‑GA | 55.48 | 59.65 |
47 | Pioglitazone | Tablet 45 mg (as hydrochloride) | Oral | Pizaccord | 55.48 | 59.65 |
47A | Pioglitazone | Tablet 45 mg (as hydrochloride) | Oral | Prioten 45 | 55.48 | 59.65 |
48 | Pioglitazone | Tablet 45 mg (as hydrochloride) | Oral | Terry White Chemists Pioglitazone | 55.48 | 59.65 |
49 | Pioglitazone | Tablet 45 mg (as hydrochloride) | Oral | Vexazone | 55.48 | 59.65 |
50 | Risedronic Acid | Tablet (enteric coated) containing risedronate sodium 35 mg | Oral | Actonel EC | 25.49 |
|
51 | Risedronic Acid | Tablet containing risedronate sodium 150 mg | Oral | Actonel Once-a-Month | 27.62 |
|
52 | Risedronic Acid | Tablet containing risedronate sodium 30 mg | Oral | Actonel | 168.36 |
|
53 | Risedronic Acid | Tablet containing risedronate sodium 35 mg | Oral | Acris Once-a-Week | 25.49 |
|
54 | Risedronic Acid | Tablet containing risedronate sodium 35 mg | Oral | APO-Risedronate | 25.49 |
|
55 | Risedronic Acid | Tablet containing risedronate sodium 35 mg | Oral | Chem mart Risedronate | 25.49 |
|
56 | Risedronic Acid | Tablet containing risedronate sodium 35 mg | Oral | Risedro once a week | 25.49 |
|
57 | Risedronic Acid | Tablet containing risedronate sodium 35 mg | Oral | Risedronate Sandoz | 25.49 |
|
58 | Risedronic Acid | Tablet containing risedronate sodium 35 mg | Oral | Risedronate-GA | 25.49 |
|
59 | Risedronic Acid | Tablet containing risedronate sodium 35 mg | Oral | Terry White Chemists Risedronate | 25.49 |
|
60 | Risedronic Acid | Tablet containing risedronate sodium 5 mg | Oral | Actonel | 25.49 |
|
Schedule 2 Brands of pharmaceutical items – unadjusted price reduction is less than 10%
Column 1 | Column 2 | Column 3 | |||
Item | Brand of Pharmaceutical Item | Weighted average disclosed price | |||
| Listed Drug | Form | Manner of administration | Brand |
|
1 | Perindopril with amlodipine | Tablet containing 10 mg perindopril arginine with 10 mg amlodipine (as besylate) | Oral | Coveram | 27.36 |
2 | Perindopril with amlodipine | Tablet containing 10 mg perindopril arginine with 10 mg amlodipine (as besylate) | Oral | Reaptan 10/10 | 27.36 |
3 | Perindopril with amlodipine | Tablet containing 10 mg perindopril arginine with 5 mg amlodipine (as besylate) | Oral | Coveram | 21.45 |
4 | Perindopril with amlodipine | Tablet containing 10 mg perindopril arginine with 5 mg amlodipine (as besylate) | Oral | Reaptan 10/5 | 21.45 |
5 | Perindopril with amlodipine | Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besylate) | Oral | Coveram | 22.67 |
6 | Perindopril with amlodipine | Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besylate) | Oral | Reaptan 5/10 | 22.67 |
7 | Perindopril with amlodipine | Tablet containing 5 mg perindopril arginine with 5 mg amlodipine (as besylate) | Oral | Coveram | 16.73 |
8 | Perindopril with amlodipine | Tablet containing 5 mg perindopril arginine with 5 mg amlodipine (as besylate) | Oral | Reaptan 5/5 | 16.73 |
Notes to the National Health (Weighted average disclosed price – interim supplementary disclosure cycle) Determination 2012 (PB 58 of 2012)
Note 1
The National Health (Weighted average disclosed price – interim supplementary disclosure cycle) Determination 2012 (PB 58 of 2012) (in force under subsection 99ADB(4) and paragraph 99ADH(1)(aa) of the National Health Act 1953) as shown in this compilation is amended as indicated in the Tables below.
Table of Instruments
Title | Date of FRLI registration | Date of | Application, saving or |
PB 58 of 2012 | 22 Aug 2012 (see F2012L01731) | 23 Aug 2012 |
|
PB 70 of 2012 | 21 Sept 2012 (see F2012L01907) | 22 Sept 2012 | — |
PB 98 of 2012 | 5 Nov 2012 (see F2012L02147) | 5 Nov 2012 | — |
Table of Amendments
ad. = added or inserted am. = amended rep. = repealed rs. = repealed and substituted | |
Provision affected | How affected |
Schedule 1 |
|
Schedule 1............ | am. PB 70 and 98 of 2012 |